Plain-English translation of ·
This research is testing a new blood test — called PSRscore — that measures immune proteins in your blood to predict whether chemotherapy or chemotherapy plus immunotherapy will shrink your gastric cancer. The test was developed based on earlier research and is now being validated in a larger group of patients to confirm it works reliably.
Not all gastric cancer patients respond the same way to chemotherapy or immunotherapy. This trial exists to develop a blood test that can predict ahead of time which patients will benefit most from treatment, so doctors can personalize care and avoid ineffective treatments.
You likely qualify if…
You likely don't qualify if…
You will have a blood sample taken before you start chemotherapy or chemotherapy plus immunotherapy — this sample will be tested for immune proteins. You will then receive your standard cancer treatment as planned by your doctor. After treatment, your tumor will be evaluated to see how well it responded. The study team will use your blood test results and treatment outcome to help validate whether the PSRscore can predict who benefits most from this therapy.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China